IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors - 2018
March 29, 2018 | Online

Overview

In this one hour webinar, we will review and highlight the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors".  We will discuss the updated guideline in terms of the evidence-based standards for clinical molecular testing of non-small cell lung cancers (NSCLC) that effectively guides targeted therapy and treatment.  We will identify where the guideline strengthens or reaffirms the 2013 recommendations for patients with lung adenocarcinoma, as well recommendations for testing for several new genes.  The latest evidence supporting these new testing technologies will be discussed, as will the anticipated impact on optimal patient care.

What you should expect to learn

After viewing this webinar attendees will be able to: 

  • Inform and educate clinicians as to updates and revisions of their Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors.
  • Review updated evidence and testing for new genes. 
  • Provide a multi-disciplinary perspective of the use and benefit of molecular testing.

Yasushi Yatabe, MD, PhD

Chief, Department of Pathology and Molecular Diagnostics
Aichi Cancer Center
Nagoya, Japan

Contact